🚨 #ESMO26 INTerpath-001 leaked before the embargo, so @myESMO released it early ➡️ Intismeran (mRNA-4157) + pembro vs placebo + pembro, adjuvant stage IIB-IV #melanoma • 24-mo RFS 82.2% vs 70.0% | HR 0.58 • 24-mo DMFS 88.5% vs 80.2% | HR 0.62 • G≥3 AEs 23.6% vs 20.3% 👇👇